OBJECTIVES: In order to control Medical Devices (MDs) purchasing process and to rationalize the MDs evaluation process, the Verona Hospitals (2 accounting for 1.700 beds), have set up a Medical Devices Committee (MDC). MDC members, who have expertise in a broad range of disciplines, evaluate MDs according to Health Technology Assessment (HTA) criteria. This study is concerned with the use of economic evaluations in policy decision making of MDC. METHODS: We developed a DataBase to record all economic evidences considered by MDC from January 2009 to April 2010 for each MD evaluated: health economics analysis in literature (cost effectiveness, cost-to-cost etc), cost information (price, costs impact etc) and Disease Related Group (DRG) simulation. We verified also the presence and costs of current alternative treatments. RESULTS: Among 37 MDs evaluated 30 technologies had at least a current alternative treatment in Hospital formulary (81.1%); MDC always considered at least the price of MDs, costs impact of introducing a new MD and costs when compared with alternative/current treatments (100%). For 23 MDs the management office individuated the DRG value (62.2%) and for 12 of them (32.4%) verified whether DRG covered direct costs. Only for 4 MDs (10.8%) was possible finding at least an economic study in literature (2 cost-effectiveness analysis and 2 cost-to-cost analysis). CONCLUSIONS: At the moment the decisions taken by the MDC  mainly focused on the clinical benefits, on the comparison of costs vs. alternative treatments and on the incidence of the DM cost on the DRG tariff. The economic evidences seldom influence the opinion of MDC, most of all because the clinical value of DM is not always supported by economic evidences. Recently, technology application form has been modified including questions about the potential savings derived by the new technology, economic studies (also not published) and Budget Impact analysis.